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Abstract
The number of heart transplant candidates and transplants performed con-
tinued to rise each year. In 2015, 2819 heart transplants were performed. In
addition, the number of new adult candidates on the waiting list increased
51% since 2004. The number of adult heart transplant survivors continued
to increase, and in 2015, 29,172 recipients were living with heart transplants.
Patient mortality following transplant has declined. The number of pediatric
candidates and transplants performed also increased. New listings for pedi-
atric heart transplants increased from 451 in 2004 to 644 in 2015. The number
of pediatric heart transplants performed each year increased from 297 in 2004
to 460 in 2015. Among pediatric patients who underwent transplant in 2014,
death occurred in 7.2% at 6 months and 9.6% at 1 year.
Keywords: End-stage heart failure, heart transplant, transplant outcomes,
ventricular assist device.
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1 Introduction
Heart transplant continues to afford advanced heart failure patients the best option for long-
term survival. The number of heart transplant candidates who are listed and the number
of heart transplants performed continue to increase. Mechanical circulatory support has
provided attractive alternatives for heart failure patients who do not qualify for transplant
and a mechanism for longer survival while awaiting transplant for those who do. The
number of left ventricular assist devices (LVADs) implanted worldwide exceeds 20,000,
and the number of candidates and recipients with VADs has increased dramatically. More
patients are undergoing transplant at higher urgency categories and waiting times are
increasing. Despite this, posttransplant survival is improving and waitlist mortality has
declined. Recent efforts to revise the heart allocation system are anticipated to provide
better risk stratification and affect the waiting time of the most critically ill patients. In this
report, we highlight the most significant trends in heart transplant over the past decade.
2 Adult Heart Transplant
2.1 Waitlist Trends: New Listings, Time to Transplant, and
Waitlist Mortality
The number of candidates awaiting heart transplant has steadily increased since 2007
(Figure HR 2). Between 2004 and 2015, the number of new active listings increased by
51% (Figure HR 1). The number of candidates actively awaiting heart transplant on
December 31 increased 90% from 1525 in 2004 to 2904 in 2015; however, the number of
inactive candidates decreased 39% during that period (Figure HR 2). The heart transplant
waiting list is aging, with a slow but steady increase in numbers of candidates aged 65
years or older. In 2015, 18% of candidates were aged 65 years or older; however, most
were aged 50 to 65 years (Figure HR 3). Ethnic diversity is increasing. In 2004, 74.3% of
candidates were white. In 2015, the proportion of white candidates declined to 62.6% due
to increased proportions of all ethnic groups, but most notably of black candidates, whose
proportion increased from 15.4% in 2004 to 24.9% in 2015 (Figure HR 4). Cardiomyopathy
remained the most prevalent indication for transplant and its proportion increased to 57.8%
of candidates in 2015 (Figure HR 5). The proportion of candidates on the waiting list for
less than 1 year has fluctuated, peaking at 64.8% in 2009 and declining since to 59.9%,
while the proportion on the list for 1 to 2 years increased to 20.1% (Figure HR 6). Similar
fluctuations occurred for candidates listed for 2 to 4 years, with a slight overall increase, but
a continuing decrease in those listed for 5 or more years. The trends among candidates at
the highest urgency categories continued to be remarkable. The proportion of status 1A and
1B candidates has almost doubled since 2004 (Figure HR 7). In 2015, 43.9% of candidates
were status 1A and 30.9% were status 1B, compared with 22.0% and 15.8%, respectively,
in 2004. Status 2 candidates have declined from 37.3% to 17.3%. Inactive candidates were
much rarer, only 8.0% in 2015. Sex distribution remained stable (Figure HR 9), while
use of VADs, as reported at listing, continued to increase, to 29.4% of candidates in 2015,
compared with only 18.1% in 2010 (Figure HR 8).
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Over the past decade, heart transplant rates (Figure HR 11, Figure HR 12, Figure HR
13) peaked at 149 transplants per 100 waitlist years in 2007, and gradually declined to
79.3 in 2015, with similar trends in many subgroups (Figure HR 13). Candidates aged
65 years or older underwent transplant at a higher rate, 84.8 per 100 waitlist years, than
the other age groups (Figure HR 11). The transplant rate was lowest among candidates
aged 18 to 34 years. In 2015, wide variability remained in transplant rates by blood type
(Figure HR 12). Candidates with blood type AB underwent heart transplant at a rate
of 281.8 per 100 waitlist years, more than 5-fold higher than for those with blood type
O, 55.5 per 100 waitlist years. Candidates with blood type A underwent transplant at a
rate of 99.7 per 100 waitlist years. Finally, although transplant rates have declined among
all status groups since 2006, the gap has widened between status 1A and 1B candidates
(Figure HR 13). In 2015, the transplant rate among status 1A candidates was 406.1 per
100 waitlist years, compared with 43.1 for status 1B candidates and 7.0 for candidates
listed as status 2. Geographic variability in access to donor hearts persisted. On average,
51.1% of candidates listed in 2014 underwent transplant in less than 1 year; however, the
proportion of candidates undergoing transplant within this time frame varied from 14.3%
to 100% depending on the donation service area (DSA) (Figure HR 20). Among DSAs
with more than 10 candidates, the proportion of candidates undergoing transplant in less
than 1 year ranged from 18.8% to 69.8%.
Of candidates listed in 2012, 54.3% underwent transplant during the first year on the
waiting list, 30.7% were still waiting, and 7.8% had died (Figure HR 14). At 3 years,
10.1% had died, 13.5% had been removed from the list, 67.0% had undergone transplant,
and 9.4% were still waiting.
In 2004, approximately 50% of candidates had undergone transplant within 6 months
of listing; however, in 2014, this proportion declined to only 36.8% (Figure HR 19). Among
candidates listed in 2014, 48.2% had undergone transplant within a year, compared with
60.2% of candidates listed in 2004. Despite a decline in 2006-2007, the median time to
transplant has increased substantially since 2004-2005, from 5.3 months to 12.4 months in
2014-2015 (Figure HR 15). Women waited 9.9 months and men almost 3 months longer.
Candidates with blood type AB waited 2.9 months and those with blood type O 22.3
months (Figure HR 16). Candidates listed as status 1A waited 3.7 months; those listed as
status 1B waited substantially longer, 11.4 months (Figure HR 17). Time to transplant also
varied by body mass index (BMI); candidates with BMI ≥ 31 kg/m2 waited 20.5 months,
and those with BMI 23 kg/m2 or less waited 6.4 months (Figure HR 18). Candidates with
BMI 24-26 kg/m2 waited a median of 9.8 months.
Pretransplant mortality continued to decline and reached 10.6 per 100 waitlist years
in 2014-2015 (Figure HR 21). While pretransplant mortality declined in most subgroups
over the past 10 years, increases occurred in the most recent era for candidates aged 50-
64 years, candidates with congenital heart disease (Figure HR 24), inactive candidates
(Figure HR 25), and women (Figure HR 23). Inactive candidates make up one of the
few subgroups with fairly consistent increases in pretransplant mortality over the past
10 years, 26.8 deaths per 100 waitlist years in 2014-2015, compared with 15.5 in 2004-
2005. In the most recent 2-year period, the pretransplant mortality rate was lowest for
candidates aged 18 to 34 years, 8.5 per 100 waitlist years. Of note, pretransplant mortality
among candidates with VADs at listing has steadily declined and was 8.5 deaths per 100
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waitlist years in 2014-2015, compared with 11.4 among candidates without VADs (Figure
HR 26). This should be interpreted cautiously, however, since candidates without a VAD
at listing may have received one after listing. Also notable, pretransplant mortality among
status 1A candidates reached a low of 16.4 deaths per 100 waitlist years, still substantially
higher than among status 1B (4.5) and 2 (3.5) candidates. The high mortality among
inactive candidates suggests that many were too ill to be made active. As with time to
transplant, pretransplant mortality varied geographically. Pretransplant mortality based
on DSA ranged from 2.9 to 22.8 deaths per 100 waitlist years (Figure HR 27). Deaths
within 6 months of removal from the waiting lists have fluctuated, peaking at 33.4% in
2013 and declining to 21.4% in 2015 (Figure HR 28). The overall increase since 2005 is
mostly due to increases in death after removal among inactive candidates; this group has
made up over half of the deaths after removal (data not shown). Candidates at status 1A
at the time of removal had the highest percentage of deaths within 6 months after removal.
In 2015, similar to 2005, the typical heart transplant candidate was white, male, and
aged 50-64 years (Table HR 1). Since 2005, however, candidates have been more likely
to be diagnosed with cardiomyopathy, be listed as status 1A or 1B, and have a VAD. In
2015, 43.8% of candidates were listed as status 1B, compared with 11.3% in 2005. The
proportion of candidates listed as status 1A increased from 1.9% to 10.0% during this time.
The number of candidates with VADs increased from 138 in 2005 to 1174 in 2015.
2.2 Donor Trends
Overall, the deceased heart donor rate was 2.8 per 1000 deaths, but it varied by state,
ranging from 0.09 to 4.94 per 1000 deaths (Figure HR 31). Forty-nine percent of donors
were aged 18 to 34 years (Figure HR 29). Rates of hearts recovered for transplant but not
transplanted reached a nadir in 2008-2011 and have trended up since (Figure HR 32). In
2014-2015, 1.1% of recovered hearts were not transplanted. The upswing is most notable
among age groups 18 to 34 and 50 years or older.
Head trauma remained the most common cause of death among heart donors; however,
an increasing proportion of deaths were due to anoxia, 33% in 2015 (Figure HR 33). Since
2004, anoxia has tripled in prevalence as cause of death, surpassing cerebrovascular accident
and stroke.
2.3 Overall Trends in Heart Transplant
In 2015, 2819 heart transplants were performed, 460 of which were in pediatric recipients, an
increase of 37.2% since 2004 (Figure HR 34). Although recipients aged 50 to 64 years made
up the greatest proportion of heart transplant recipients, a relatively large increase occurred
since 2014 among recipients aged 35 to 49 years (Figure HR 35). Increases occurred in all
subgroups since 2004, except for recipients with valvular heart disease for whom, despite
yearly variation, the overall trend was downward (Figure HR 38).
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2.4 Recipient Characteristics
In 2015, most heart transplant recipients were aged 50-64 years; however, the proportion
aged 65 years or older increased to 18.9%, compared with 11.4% in 2005 (Table HR 5).
The typical recipient was white, male, with blood type A or O, representing no substantial
change since 2005. However, a greater proportion of recipients were non-white, and more
recipients underwent transplant at status 1A than in 2005. The proportion of recipients
who underwent transplant at status 2 declined precipitously from 28.8% in 2005 to 2.6% in
2015. VADs at transplant were much more prevalent in 2015 than in 2005, 48.4% vs. 28.9%.
In addition, coronary artery disease was less prevalent among recipients in 2015 than in
2005. Most patients had private payers; however, in 2005 56.9% of recipients had private
payers and 48.7% in 2015, due to more recipients with Medicare. Retransplant declined
since 2005 to 2.9% of heart transplants in 2015. Heart-lung transplants declined, but the
number of heart-kidney transplants increased from 53 to 140 and the number of heart-liver
transplants from 5 to 27. Waiting time increased, as evidenced by a shift in the proportion
of recipients who waited longer than 6 months. The number and proportion of patients on
any form of life support increased from 1547 (76.8%) in 2005 to 1990 (84.4%) in 2015 (Table
HR 4). Most patients on life support had either intravenous inotropes or LVADs. In 2015,
the proportion of recipients with an LVAD at transplant increased to 44.8%. Intra-aortic
balloon pumps also increased from 5.0% to 7.0%, extracorporeal membrane oxygenation
was similar at 1.0% both years, and the proportion of total artificial hearts increased from
1.3% to 1.7%. Ventilator use declined from 2.9% to 1.0%
2.5 Posttransplant Survival and Morbidity
One-year survival for patients who underwent heart transplant 2008-2010 was 89.6%, 3-year
survival was 82.9%, and 5-year survival 77.0% (Figure HR 47). One-year survival among
many subgroups was similar to overall survival but tended to be lower among recipients
who were aged 65 years or older (Figure HR 45), black (Figure HR 46), or status 2 at
transplant (Figure HR 50). After the first year posttransplant, however, survival declined
more rapidly for recipients aged 18 to 35 years, black recipients, and retransplant recipients.
By 5 years, survival was 73.8% for recipients aged 18 to 34 years, 72.2% for black recipients,
and 74.5% among retransplant recipients. Survival did not differ meaningfully between the
medical urgency categories at any time, but tended to be lower for status 2 recipients.
Since 2004, patient death after transplant decreased overall at 6 months and at 1, 3, and
5 years, despite slight increases in 6-month and 1- and 3-year mortality between 2013 and
2014 (Figure HR 51). The number of heart transplant survivors has increased since 2004.
On June 30, 2015, 29,172 heart transplant recipients were alive with a functioning graft;
most had undergone transplant at age 50 years or older (Figure HR 52).
The incidence of acute rejection in the first year posttransplant decreased from 25.1%
among recipients who underwent transplant 2009-2010 to 23.0% among recipients who
underwent transplant 2013-2014 (Figure HR 53). Acute rejection was least prevalent in
recipients aged 65 years or older, occurring in only 18.3%, and most prevalent in recipients
aged 18 to 34 years, 30.2%. Posttransplant lymphoproliferative disorder (PTLD) remained
uncommon, with an overall cumulative incidence of only 1% by 5 years posttransplant (Fig-
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ure HR 54). The most common documented causes of death in the first posttransplant year
were infection, cardiovascular/cerebrovascular disease, and graft failure (Figure HR 55). By
the second year, cardiovascular/cerebrovascular disease was the leading documented cause
of death through year 5 (Figure HR 56). Malignancy was relatively infrequent as a cause
of death, 1.7% of deaths at 5 years.
3 Pediatric Heart Transplant
3.1 Pediatric Waitlist Trends
In 2015, the number of new pediatric candidates added to the heart transplant waiting list
continued its increase to the highest number yet, 644, with few at inactive status (Figure
HR 57). At year-end 2015, 370 candidates listed before their eighteenth birthdays were
awaiting heart transplant, 62.4% active (Figure HR 58). The largest pediatric age group
on the waiting list in 2015 was 11 to 17 years (34.0%), followed by ages younger than 1
year (25.8%), 1 to 5 years (24.2%), and 6 to 10 years (16.0%) (Figure HR 59). Over half
of heart transplant candidates were white, 21.2% were Hispanic, 17.3% were black, and
5.2% were Asian (Figure HR 60). The proportion of waitlist candidates aged younger than
1 year almost doubled from 7.6% on December 31, 2005, to 14.0% on December 31, 2015
(Table HR 7). The proportion of male candidates remained high, 60.7%. The proportion
of Hispanic candidates increased from 16.4% on December 31, 2005, to 24.9% on December
31, 2015. For candidates waiting on December 31, 2015, congenital defect was the leading
cause of heart disease (53.6%). Thirty-three percent of candidates were listed as status
1A in 2015, compared with only 10.5% in 2005. Increases in status 1B listings were also
increased, from 7.1% in 2005 to 13.4% in 2015.. The percentage of candidates using VADs
at the time of listing increased from 2.1% in 2005 to 4.4% in 2015. Listings for heart-only
transplants increased from 90.3% in 2005 to 98.4% in 2015, and listings for heart-lung and
heart-kidney transplants decreased to less than 1%. Among candidates removed from the
waiting list in 2015, 463 (72.9%) were removed due to undergoing transplant, 80 (12.6%)
died, 48 (7.6%) were removed due to improved condition, and 24 (3.8%) were considered
too sick to undergo transplant (Table HR 9).
Nearly 75% of candidates newly listed in 2012 underwent transplant within 3 years,
9.7% died, 11.7% were removed from the list, and 4.3% were still waiting (Figure HR
64). The rate of heart transplants among active pediatric waitlist candidates decreased
from a peak of almost 300 per 100 waitlist years in 2006 to 189 per 100 waitlist years in
2015, likely attributable to a growing waiting list. Transplant rates varied by age, with
the highest rates for candidates aged younger than 1 year, at 401 transplants per 100
waitlist years in 2015, followed by candidates aged 11 to 17 years, at 187 transplants per
100 waitlist years (Figure HR 65). Pretransplant mortality remained stable at 21.8 deaths
per 100 waitlist years in 2014-2015 (Figure HR 66). The pretransplant mortality rate was
highest for candidates aged younger than 1 year, at 42.9 deaths per 100 waitlist years in
2014-2015, followed by candidates aged 1 to 5 years at 18.5, 6 to 10 years at 16.8, and
11 to 17 years at 8.3. Regarding cause of disease, pretransplant mortality was highest
for candidates with dilated myopathy/myocarditis or congenital defects (Figure HR 68).
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Pretransplant mortality was highest for status 1A candidates (34.1 deaths per 100 waitlist
years) and inactive candidates (32.0), compared with 4.3 and 0.6 for status 1B and status
2 candidates, respectively (Figure HR 69).
3.2 Pediatric Transplant
The number of pediatric heart transplants performed each year increased from 297 in 2004
to 460 in 2015 (Figure HR 70). In 2015, 36 of 127 total heart transplant centers performed
pediatric heart transplants exclusively, compared with 23 centers in 2004 (Figure HR 71).
Over the past decade, the age, sex, and race of pediatric heart transplant recipients changed
little. Congenital defects remained the most common primary cause of disease, affecting
45.3% of recipients who underwent transplant in 2012-2015. The proportion of ABO-
incompatible transplants in 2012-2015 was 3.7%, increased from 1.7% a decade earlier.
The proportion of patients who underwent transplant as status 1A increased from 72.0% in
2002-2005 to 88.6% in 2012-2015. VAD use tripled from only 8.8% of transplant recipients
in 2002-2005 to 24.6% in 2012-2015 (Table HR 10).
3.3 Pediatric Immunosuppression and Outcomes
In 2015, the most common induction therapy was T-cell depleting agents, used in 64.2%
of heart transplant recipients, followed by interleukin-2 receptor antagonists (IL-2-RA)
in 14.4%. No induction therapy was reported in 22.8% of recipients (Figure HR 72).
Regarding induction use by panel-reactive antibody (PRA), T-cell depleting agents were
generally used more frequently for the most sensitized patients, while IL-2-RA was used
less frequently for sensitized patients (Figure HR 77). The initial immunosuppression
agents used most commonly in 2015 were tacrolimus (88.7%, Figure HR 73), mycophenolate
(93.1%, Figure HR 74), and steroids (60.0%, Figure HR 76). In 2014, mammalian target
of rapamycin inhibitors were used in only 1.2% of recipients at the time of transplant, but
use increased to 13.8% at 1 year posttransplant (Figure HR 75). Among patients who
underwent transplant in 2014, steroid use was 67.2% at transplant and 58.7% at 1 year
posttransplant (Figure HR 76).
Among pediatric heart transplant recipients from 2011 to 2015, 46.5% were cytomegalovirus
(CMV) negative and 43.4% were Epstein-Barr virus (EBV) negative (Table HR 12). The
combination of a CMV-positive donor and CMV-negative recipient occurred in 23.5% of
transplants; for EBV, this occurred in 29.7% of transplants.
Recipient death occurred in 7.2% at 6 months and 9.6% at 1 year among heart trans-
plants performed in 2014, in 10.6% at 3 years for transplants performed in 2012, in 14.9%
at 5 years for transplants performed in 2010, and in 33.6% at 10 years for transplants
performed in 2005 (Figure HR 81). Overall, 1-year and 5-year patient survival were 88.7%
and 77.2%, respectively, among recipients who underwent transplant in 2003-2010 (Figure
HR 82). By age, 5-year patient survival was 71.2% for recipients aged younger than 1 year,
78.4% for ages 1 to 5 years, 87.5% for ages 6 to 10 years, and 77.4% for ages 11 to 17 years
(Figure HR 82). The leading identified causes of death in the first 5 years posttransplant
were graft failure (5.4%) and cardio/cerebrovascular disease (4.8%) (Figure HR 84).
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The incidence of PTLD among EBV-negative recipients was 5.5% at 5 years posttrans-
plant, compared with 2.5% among EBV-positive recipients (Figure HR 80). The overall
incidence of first acute rejection in the first posttransplant year was 17.8% in 2013-2014
(Figure HR 79). By age, the highest incidence of rejection was 25.6% in the group aged 6
to 10 years.
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Figure HR 1. New adult candidates added to the heart transplant waiting
list. A new candidate is one who first joined the list during the given year, without
having been listed in a previous year. Previously listed candidates who underwent
transplant and subsequently relisted are considered new. Candidates concurrently
listed at multiple centers are counted once. Active and inactive patients are included.

























Figure HR 2. Adults listed for heart transplant on December 31 each
year. Candidates concurrently listed at multiple centers are counted once. Those
with concurrent listings and active at any program are considered active.
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Figure HR 3. Distribution of adults waiting for heart transplant by age.
Candidates waiting for transplant at any time in the given year. Candidates listed
concurrently at multiple centers are counted once. Age is determined at the later
of listing date or January 1 of the given year. Active and inactive candidates are
included.
2004 2006 2008 2010 2012 2014 2016
●



















Figure HR 4. Distribution of adults waiting for heart transplant by race.
Candidates waiting for transplant at any time in the given year. Candidates listed
concurrently at multiple centers are counted once. Active and inactive candidates
are included.
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Figure HR 5. Distribution of adults waiting for heart transplant by diag-
nosis. Candidates waiting for transplant at any time in the given year. Candidates
listed concurrently at multiple centers are counted once. Active and inactive patients
are included. CAD, coronary artery disease.



























Figure HR 6. Distribution of adults waiting for heart transplant by wait-
ing time. Candidates waiting for transplant at any time in the given year. Candi-
dates listed concurrently at multiple centers are counted once. Time on the waiting
list is determined at the earlier of December 31 or removal from the waiting list.
Active and inactive candidates are included.
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Figure HR 7. Distribution of adults waiting for heart transplant by med-
ical urgency. Candidates waiting for transplant at any time in the given year.
Candidates listed concurrently at multiple centers are counted once. Medical ur-
gency status is the most severe during the year. Active and inactive patients are
included.
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Figure HR 8. Distribution of adults waiting for heart transplant by VAD
status at listing. Candidates waiting for transplant at any time in the given year.
Candidates listed concurrently at multiple centers are counted once. Active and
inactive patients are included. VAD, ventricular assist device.
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Figure HR 9. Distribution of adults waiting for heart transplant by sex.
Candidates waiting for transplant at any time in the given year. Candidates listed
concurrently at multiple centers are counted once. Active and inactive patients are
included.
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Figure HR 10. Distribution of adults waiting for heart transplant by blood
type. Candidates waiting for transplant at any time in the given year. Candidates
listed concurrently at multiple centers are counted once. Active and inactive patients
are included.
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Figure HR 11. Deceased donor heart transplant rates among active adult
waitlist candidates by age. Transplant rates are computed as the number of
deceased donor transplants per 100 patient-years of active wait time in a given year.
Individual listings are counted separately. Age is determined at the later of listing
date or January 1 of the given year. Rates with less than 10 patient-years of exposure
are not shown.




































Figure HR 12. Deceased donor heart transplant rates among active adult
waitlist candidates by blood type. Transplant rates are computed as the number
of deceased donor transplants per 100 patient-years of active wait time in a given
year. Individual listings are counted separately. Rates with less than 10 patient-years
of exposure are not shown.
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Figure HR 13. Deceased donor heart transplant rates among active adult
waitlist candidates by medical urgency. Transplant rates are computed as the
number of deceased donor transplants per 100 patient-years of active wait time in
a given year. Individual listings are counted separately. Rates with less than 10
patient-years of exposure are not shown.


















Figure HR 14. Three-year outcomes for adults waiting for heart trans-
plant, new listings in 2012. Adults waiting for heart transplant and first listed
in 2012. Candidates concurrently listed at more than one center are counted once,
from the time of earliest listing to the time of latest removal. DD, deceased donor.
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Figure HR 15. Median months to heart transplant for waitlisted adults
by sex. Observations censored on December 31, 2015; Kaplan-Meier competing risk
methods used to estimate time to transplant. Analysis performed per candidate, not
per listing. If an estimate is not plotted, 50% of the cohort listed in that year had


































Figure HR 16. Median months to heart transplant for waitlisted adults by
blood type. Observations censored on December 31, 2015; Kaplan-Meier competing
risk methods used to estimate time to transplant. Analysis performed per candidate,
not per listing. If an estimate is not plotted, 50% of the cohort listed in that year
had not undergone transplant by the censoring date. Only the first transplant is
counted.
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Figure HR 17. Median months to heart transplant for waitlisted adults
by medical urgency at listing. Observations censored on December 31, 2015;
Kaplan-Meier competing risk methods used to estimate time to transplant. Analysis
performed per candidate, not per listing. If an estimate is not plotted, 50% of the
cohort listed in that year had not undergone transplant by the censoring date. Only

































Figure HR 18. Median months to heart transplant for waitlisted adults
by BMI at listing. Observations censored on December 31, 2015; Kaplan-Meier
competing risk methods used to estimate time to transplant. Analysis performed
per candidate, not per listing. If an estimate is not plotted, 50% of the cohort listed
in that year had not undergone transplant by the censoring date. Only the first
transplant is counted.
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Figure HR 19. Percentage of adults who underwent deceased donor heart
transplant within a given time period of listing. Candidates concurrently
listed at more than one center are counted once, from the time of earliest listing to
the time of latest removal.
No data
14.3 100.0
34.5 43.8 52.2 63.2
Figure HR 20. Percentage of adults who underwent deceased donor heart
transplant within 1 year of listing in 2014 by DSA. Candidates listed con-
currently in a single DSA are counted once in that DSA, from the time of earliest
listing to the time of latest removal; candidates listed in multiple DSAs are counted
separately per DSA.
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Figure HR 21. Pretransplant mortality rates among adults waitlisted for
heart transplant by age. Mortality rates are computed as the number of deaths
per 100 patient-years of waiting in the given year. Individual listings are counted
separately. Rates with less than 10 patient-years of exposure are not shown. Age is
































Figure HR 22. Pretransplant mortality rates among adults waitlisted for
heart transplant by race. Mortality rates are computed as the number of deaths
per 100 patient-years of waiting in the given year. Individual listings are counted
separately. Rates with less than 10 patient-years of exposure are not shown.
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Figure HR 23. Pretransplant mortality rates among adults waitlisted for
heart transplant by sex. Mortality rates are computed as the number of deaths
per 100 patient-years of waiting in the given year. Individual listings are counted

































Figure HR 24. Pretransplant mortality rates among adults waitlisted for
heart transplant by diagnosis. Mortality rates are computed as the number of
deaths per 100 patient-years of waiting in the given year. Individual listings are
counted separately. Rates with less than 10 patient-years of exposure are not shown.
CAD, coronary artery disease.
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Figure HR 25. Pretransplant mortality rates among adults waitlisted for
heart transplant by medical urgency. Mortality rates are computed as the
number of deaths per 100 patient-years of waiting in the given year. Individual






























Figure HR 26. Pretransplant mortality rates among adults waitlisted for
heart transplant by VAD at listing. Mortality rates are computed as the number
of deaths per 100 patient-years of waiting in the given year. Individual listings are
counted separately. Rates with less than 10 patient-years of exposure are not shown.
VAD, ventricular assist device.
22
     
No data
2.9 22.8
6.6 8.9 10.8 13.9
Figure HR 27. Pretransplant mortality rates among adults waitlisted for
heart transplant in 2014-2015, by DSA. Mortality rates are computed as the
number of deaths per 100 patient-years of waiting in the given year. Individual
listings are counted separately. Rates with less than 10 patient-years of exposure are
not shown.





























Figure HR 28. Deaths within six months after removal among adult
heart walitlist candidates. Denominator includes only candidates removed from
the waiting list for reasons other than transplant or death while on the list.
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Figure HR 29. Deceased heart donors by age. Deceased donors whose hearts
were recovered for transplant.
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Figure HR 30. Deceased heart donors by race. Deceased donors whose hearts
were recovered for transplant.
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Figure HR 31. Deceased donor heart donation rates (per 1000 deaths)
by state, 2012-2014. Numerator: Deceased donors aged < 70 years, by state
of death, whose heart was recovered for transplant from 2012 through 2014. De-
nominator: US deaths aged < 70 years, by state of death, from 2012 through
2014. State death data by age obtained through agreement with NAPHSIS
(http://www.naphsis.org/programs/vital-statistics-data-research-request-process).





















Figure HR 32. Rates of hearts recovered for transplant and not trans-
planted by age. Percentages of hearts not transplanted out of all hearts recovered
for transplant.
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Figure HR 33. Cause of death among deceased heart donors. Deceased
donors whose hearts were transplanted. CNS, central nervous system; CVA, cere-
brovascular accident.
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Figure HR 34. Total heart transplants. All heart transplant recipients, includ-
ing adult and pediatric, retransplant, and multi-organ recipients.
26
     
2004 2006 2008 2010 2012 2014 2016
● ● ●
●























Figure HR 35. Total heart transplants by age. All heart transplant recipients,
including adult and pediatric, retransplant, and multi-organ recipients.




























Figure HR 36. Total heart transplants by sex. All heart transplant recipients,
including adult and pediatric, retransplant, and multi-organ recipients.
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Figure HR 37. Total heart transplants by race. All heart transplant recipients,
including adult and pediatric, retransplant, and multi-organ recipients.



























Figure HR 38. Total heart transplants by diagnosis. All heart transplant
recipients, including adult and pediatric, retransplant, and multi-organ recipients.
CAD, coronary artery disease.
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Figure HR 39. Induction agent use in adult heart transplant recipients.
Immunosuppression at transplant reported to the OPTN. IL2-RA, interleukin-2 re-
ceptor antagonist.

























Figure HR 40. Calcineurin inhibitor use in adult heart transplant recipi-
ents. Immunosuppression at transplant reported to the OPTN.
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Figure HR 41. Anti-metabolite use in adult heart transplant recipients.
Immunosuppression at transplant reported to the OPTN. Mycophenolate includes
mycophenolate mofetil and mycophenolate sodium.



















Figure HR 42. mTOR inhibitor use in adult heart transplant recipients.
Immunosuppression at transplant reported to the OPTN. One-year posttransplant
data are limited to patients alive with graft function at 1 year posttransplant. mTOR,
mammalian target of rapamycin.
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Figure HR 43. Steroid use in adult heart transplant recipients. Immuno-
suppression at transplant reported to the OPTN. One-year posttransplant data are
limited to patients alive with graft function at 1 year posttransplant.










Figure HR 44. Total HLA A, B, and DR mismatches among adult de-
ceased donor heart transplant recipients, 2011-2015. Donor and recipient
antigen matching is based on OPTN antigen values and split equivalences policy as
of 2015.
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Figure HR 45. Patient survival among adult heart transplant recipients,
2008-2010, by age. Patient survival estimated using unadjusted Kaplan-Meier
methods. For recipients of more than one transplant during the period, only the first
is considered.


















Figure HR 46. Patient survival among adult heart transplant recipients,
2008-2010, by race. Patient survival estimated using unadjusted Kaplan-Meier
methods. For recipients of more than one transplant during the period, only the first
is considered.
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Figure HR 47. Patient survival among adult heart transplant recipients,
2008-2010, by sex. Patient survival estimated using unadjusted Kaplan-Meier
methods. For recipients of more than one transplant during the period, only the first
is considered.

















Figure HR 48. Patient survival among adult heart transplant recipients,
2008-2010, by circulatory support. Patient survival estimated using unadjusted
Kaplan-Meier methods. For recipients of more than one transplant during the pe-
riod, only the first is considered. Ventricular assist device (VAD) status at time of
transplant. IABP, intra-aortic balloon pump.
33
     














Figure HR 49. Patient survival among adult heart transplant recipients,
2008-2010, by first vs. retransplant. Patient survival estimated using unad-
justed Kaplan-Meier methods. For recipients of more than one transplant during the
period, only the first is considered.

















Figure HR 50. Patient survival among adult heart transplant recipients,
2008-2010, by medical urgency. Patient survival estimated using unadjusted
Kaplan-Meier methods. For recipients of more than one transplant during the period,
only the first is considered.
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Figure HR 51. Patient death among adult heart transplant recipients. All
adult recipients of deceased donor hearts, including multi-organ transplants. Patients
are followed until the earlier of death or December 31, 2015. Estimates computed
with Cox proportional hazards models adjusted for age, sex, and race.
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Figure HR 52. Recipients alive with a functioning heart graft on June
30 of the year, by age at transplant. Recipients are assumed to be alive with
function unless a death or graft failure is recorded. A recipient may experience a
graft failure and be removed from the cohort, undergo retransplant, and re-enter the
cohort.
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Figure HR 53. Incidence of acute rejection by 1 year posttransplant
among adult heart transplant recipients by age. Acute rejection is defined
as a record of acute or hyperacute rejection, as reported on the OPTN Transplant
Recipient Registration or Transplant Recipient Follow-up Form. Only the first re-
jection event is counted. Cumulative incidence is estimated using the Kaplan-Meier
competing risk method.
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Figure HR 54. Incidence of PTLD among adult heart transplant recipients
by recipient EBV status at transplant, 2009-2013. Cumulative incidence is
estimated using the Kaplan-Meier competing risk method. PTLD is identified as a re-
ported complication or cause of death on the OPTN Transplant Recipient Follow-up
Form or the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic
PTLD, or Hodgkin disease. Only the earliest date of PTLD diagnosis is considered.
EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative disorder.
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Figure HR 55. One-year cumulative incidence of death by cause among
adult heart recipients, 2013-2014. Primary cause of death is as reported on
the OPTN Transplant Recipient Registration and Follow-up Forms. Other causes of
death include hemorrhage, trauma, nonadherence, unspecified other, unknown, etc.
Cumulative incidence is estimated using Kaplan-Meier competing risk methods.



















Figure HR 56. Five-year cumulative incidence of death by cause among
adult heart recipients, 2009-2010. Primary cause of death is as reported on
the OPTN Transplant Recipient Registration and Follow-up Forms. Other causes of
death include hemorrhage, trauma, nonadherence, unspecified other, unknown, etc.
Cumulative incidence is estimated using Kaplan-Meier competing risk methods.
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Figure HR 57. New pediatric candidates added to the heart transplant
waiting list. A new candidate is one who first joined the list during the given
year, without having been listed in a previous year. Previously listed candidates
who underwent transplant and subsequently relisted are considered new. Candidates
concurrently listed at multiple centers are counted once. Active and inactive patients
are included. Age determined at listing.






























Figure HR 58. Pediatric candidates listed for heart transplant on Decem-
ber 31 each year. Candidates concurrently listed at multiple centers are counted
once. Those with concurrent listings and active at any program are considered active.
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Figure HR 59. Distribution of pediatric candidates waiting for heart
transplant by age. Candidates waiting for transplant at any time in the given
year. Candidates listed concurrently at multiple centers are counted once. Age is
determined at the later of listing date or January 1 of the given year. Active and
inactive candidates are included.






















Figure HR 60. Distribution of pediatric candidates waiting for heart
transplant by race. Candidates waiting for transplant any time in the given year.
Candidates listed concurrently at multiple centers are counted once. Active and
inactive candidates are included.
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Figure HR 61. Distribution of pediatric candidates waiting for heart
transplant by diagnosis. Candidates waiting for transplant any time in the given
year. Candidates listed concurrently at multiple centers are counted once. Active
and inactive candidates are included. CM, cardiomyopathy.





















Figure HR 62. Distribution of pediatric candidates waiting for heart
transplant by waiting time. Candidates waiting for transplant any time in the
given year. Candidates listed concurrently at multiple centers are counted once.
Time on the waiting list is determined at the earlier of December 31 or removal from
the waiting list. Active and inactive candidates are included.
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Figure HR 63. Distribution of pediatric candidates waiting for heart
transplant by medical urgency. Candidates waiting for transplant any time in
the given year. Candidates listed concurrently at multiple centers are counted once.
Medical urgency status is the most severe during the year. Active and inactive
patients are included.


















Figure HR 64. Three-year outcomes for newly listed pediatric candidates
waiting for heart transplant, 2012. Candidates aged 0-11 who joined the heart
or heart-lung waitlist in 2012. Candidates concurrently listed at more than one center
are counted once, from the time of earliest listing to the time of latest removal. DD,
deceased donor.
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Figure HR 65. Heart transplant rates among active pediatric waitlist
candidates by age. Transplant rates are computed as the number of deceased
donor transplants per 100 patient-years of active waiting in a given year. Individual
listings are counted separately. Age is determined at the later of listing date or





































Figure HR 66. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by age. Mortality rates are computed as the number of
deaths per 100 patient-years of waiting in the given year. Individual listings are
counted separately. Age is determined at the later of listing date or January 1 of the
given year. Rates with less than 10 patient-years of exposure are not shown.
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Figure HR 67. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by race. Mortality rates are computed as the number of
deaths per 100 patient-years of waiting in the given year. Individual listings are




































Figure HR 68. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by diagnosis. Mortality rates are computed as the number
of deaths per 100 patient-years of waiting in the given year. Individual listings are
counted separately. Rates with less than 10 patient-years of exposure are not shown.
CM, cardiomyopathy.
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Figure HR 69. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by medical urgency. Mortality rates are computed as
the number of deaths per 100 patient-years of waiting in the given year. Individual
listings are counted separately. Rates with less than 10 patient-years of exposure are
not shown.



























Figure HR 70. Pediatric heart transplants by age. All pediatric heart trans-
plant recipients, including retransplant, and multi-organ recipients.
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Figure HR 71. Number of centers performing pediatric and adult heart
transplants by center’s age mix. Adult centers transplanted only recipients aged
18 years or older. Functionally adult centers transplant 80% adults or more, and the
remainder were children aged 15-17 years. Mixed included adults and children of any
age groups. Child only centers transplanted recipeints aged 0-17 years, and small
number of adults up to age 21 years.
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Figure HR 72. Induction agent use in pediatric heart transplant recipi-
ents. Immunosuppression at transplant reported to the OPTN. IL2-RA, interleukin-
2 receptor antagonist.
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Figure HR 73. Calcineurin inhibitor use in pedatric heart transplant
recipients. Immunosuppression at transplant reported to the OPTN.























Figure HR 74. Anti-metabolite use in pedatric heart transplant recipients.
Immunosuppression at transplant reported to the OPTN. Mycophenolate includes
mycophenolate mofetil and mycophenolate sodium.
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Figure HR 75. mTOR inhibitor use in pediatric heart transplant recipi-
ents. Immunosuppression at transplant reported to the OPTN. One-year posttrans-
plant data are limited to patients alive with graft function at 1 year posttransplant.
mTOR, mammalian target of rapamycin.























Figure HR 76. Steroid use in pedatric heart transplant recipients. Immuno-
suppression at transplant reported to the OPTN. One-year posttransplant data are
limited to patients alive with graft function at 1 year posttransplant.
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Figure HR 77. Induction use by CPRA among pediatric heart transplant
recipients, 2011-2015. Collection of calculated PRA (CPRA) began March 31,
2015. Prior to that, PRA class I and II values were used. IL2-RA, interleukin-2
receptor antagonist.










Figure HR 78. Total HLA A, B, and DR mismatches among pediatric
deceased donor heart transplant recipients, 2011-2015. Donor and recipient
antigen matching is based on OPTN antigen values and split equivalences policy as
of 2015.
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Figure HR 79. Incidence of acute rejection by 1 year posttransplant
among pediatric heart transplant recipients by age. Acute rejection is defined
as a record of acute or hyperacute rejection, as reported on the OPTN Transplant
Recipient Registration Form or Transplant Recipient Follow-up Form. Only the first
rejection event is counted. Cumulative incidence is estimated using the Kaplan-Meier
competing risk method.
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Figure HR 80. Incidence of PTLD among pediatric heart transplant recip-
ients by recipient EBV status at transplant, 2003-2013. Cumulative incidence
is estimated using the Kaplan-Meier competing risk method. Posttransplant lym-
phoproliferative disorder (PTLD) is identified as a reported complication or cause of
death on the OPTN Transplant Recipient Follow-up Form or on the Posttransplant
Malignancy Form as polymorphic PTLD, monomorphic PTLD, or Hodgkin disease.
Only the earliest date of PTLD diagnosis is considered. EBV, Epstein-Barr virus.
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Figure HR 81. Patient death among pediatric heart transplant recipients.
All pediatric recipients of deceased donor hearts, including multi-organ transplants.
Patients are followed until the earlier of death or December 31, 2015. Estimates
computed with Cox proportional hazards models adjusted for age, sex, and race.


















Figure HR 82. Patient survival among pediatric deceased donor heart
transplant recipients, 2003-2010, by age. Recipient survival estimated using
unadjusted Kaplan-Meier methods.
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Figure HR 83. One-year cumulative incidence of death by cause among
pediatric heart recipients, 2013-2014. Primary cause of death is as reported on
the OPTN Transplant Recipient Registration and Follow-up Forms. Other causes of
death include hemorrhage, trauma, nonadherence, unspecified other, unknown, etc.
Cumulative incidence is estimated using Kaplan-Meier competing risk methods.



















Figure HR 84. Five-year cumulative incidence of death by cause among
pediatric heart recipients, 2009-2010. Primary cause of death is as reported on
the OPTN Transplant Recipient Registration and Follow-up Forms. Other causes of
death include hemorrhage, trauma, nonadherence, unspecified other, unknown, etc.
Cumulative incidence is estimated using Kaplan-Meier competing risk methods.
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Characteristic
2005 2015
N Percent N Percent
Age
18-34 years 296 10.9% 384 10.1%
35-49 years 627 23.1% 888 23.4%
50-64 years 1415 52.2% 1847 48.7%
≥65 years 374 13.8% 672 17.7%
Sex
Female 645 23.8% 880 23.2%
Male 2067 76.2% 2911 76.8%
Race/ethnicity
White 1976 72.9% 2347 61.9%
Black 439 16.2% 987 26.0%
Hispanic 221 8.1% 331 8.7%
Asian 57 2.1% 105 2.8%
Other/unknown 19 0.7% 21 0.6%
Diagnosis
Coronary artery disease 1112 41.0% 1256 33.1%
Cardiomyopathy 1213 44.7% 2181 57.5%
Congenital disease 153 5.6% 141 3.7%
Valvular disease 77 2.8% 43 1.1%
Other/unknown 157 5.8% 170 4.5%
Transplant history
First 2628 96.9% 3681 97.1%
Retransplant 84 3.1% 110 2.9%
Blood type
A 814 30.0% 1186 31.3%
B 257 9.5% 446 11.8%
AB 49 1.8% 79 2.1%
O 1592 58.7% 2080 54.9%
Table HR 1 Characteristics of adults on the heart transplant waiting list
on December 31, 2005 and December 31, 2015 (continued on next page).
Candidates waiting for transplant on December 31, 2005, and December 31, 2015,
regardless of first listing date; active/inactive status is on this date, and multiple
listings are not counted. VAD, ventricular assist device.
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Characteristic
2005 2015
N Percent N Percent
Wait time
< 1 year 919 33.9% 1919 50.6%
1-< 2 years 391 14.4% 884 23.3%
2-< 3 years 312 11.5% 415 10.9%
3-< 4 years 224 8.3% 214 5.6%
4-< 5 years 181 6.7% 128 3.4%
≥ 5 years 685 25.3% 231 6.1%
Medical urgency
Status 1A 52 1.9% 380 10.0%
Status 1B 306 11.3% 1659 43.8%
Status 2 904 33.3% 865 22.8%
Inactive status 1450 53.5% 887 23.4%
VAD at listing 138 5.1% 1174 31.0%
Tx type
Heart only 2553 94.1% 3531 93.1%
Heart-kidney 47 1.7% 179 4.7%
Heart-lung 102 3.8% 48 1.3%
Other 10 0.4% 33 0.9%
All candidates 2712 100.0% 3791 100.0%
Table HR 1 Characteristics of adults on the heart transplant waiting list
on December 31, 2005 and December 31, 2015 (continued from previous
page). Candidates waiting for transplant on December 31, 2005, and December
31, 2015, regardless of first listing date; active/inactive status is on this date, and
multiple listings are not counted. VAD, ventricular assist device.
55
     
Waiting list state 2013 2014 2015
Patients at start of year 3058 3339 3626
Patients added during year 3304 3613 3622
Patients removed during year 3018 3318 3457
Patients at end of year 3344 3634 3791
Table HR 2 Heart transplant waitlist activity among adults. Candidates
concurrently listed at more than one center are counted once, from the time of earliest
listing to the time of latest removal. Candidates who are listed, undergo transplant,
and are relisted are counted more than once. Candidates are not considered to be
on the list on the day they are removed; counts on January 1 may differ from counts
on December 31 of the prior year. Candidates listed for multi-organ transplants are
included.
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Removal reason 2013 2014 2015
Deceased donor transplant 2109 2229 2330
Patient died 345 375 393
Patient refused transplant 14 22 24
Improved, transplant not needed 146 201 162
Too sick for transplant 223 271 300
Other 181 220 248
Table HR 3 Removal reason among adult heart transplant candidates.
Removal reason as reported to the OPTN. Candidates with death dates that precede
removal dates are assumed to have died waiting.
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Support
2010 2015
N Percent N Percent
Any life support 1547 76.8% 1990 84.4%
Intravenous inotropes 744 36.9% 856 36.3%
Left ventricular assist device 717 35.6% 1056 44.8%
Intra-aortic balloon pump 101 5.0% 165 7.0%
Ventilator 59 2.9% 23 1.0%
Right ventricular assist device 57 2.8% 51 2.2%
Total artificial heart 26 1.3% 41 1.7%
Extra corporeal membrane oxygenation 20 1.0% 23 1.0%
Inhaled NO 9 0.4% 3 0.1%
Prostaglandins 3 0.1% 2 0.1%
Table HR 4 Adult heart recipients on circulatory support before trans-
plant. Patients may have more than one type of circulatory support.
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Characteristic
2005 2015
N Percent N Percent
Age
18-34 years 253 13.7% 227 9.6%
35-49 years 415 22.5% 506 21.4%
50-64 years 964 52.4% 1179 50.0%
≥65 years 209 11.4% 447 18.9%
Sex
Female 451 24.5% 611 25.9%
Male 1390 75.5% 1748 74.1%
Race/ethnicity
White 1326 72.0% 1483 62.9%
Black 298 16.2% 539 22.8%
Hispanic 142 7.7% 212 9.0%
Asian 61 3.3% 107 4.5%
Other/unknown 14 0.8% 18 0.8%
Diagnosis
Coronary artery disease 816 44.3% 825 35.0%
Cardiomyopathy 872 47.4% 1400 59.3%
Congenital disease 64 3.5% 75 3.2%
Valvular disease 45 2.4% 23 1.0%
Other/unknown 44 2.4% 36 1.5%
Transplant history
First 1773 96.3% 2291 97.1%
Retransplant 68 3.7% 68 2.9%
Blood type
A 785 42.6% 912 38.7%
B 260 14.1% 367 15.6%
AB 91 4.9% 151 6.4%
O 705 38.3% 929 39.4%
Table HR 5 Characteristics of adult heart transplant recipients, 2005 and
2015 (continued on next page). Adult heart transplant recipients, including re-
transplants. Ventricular assist device (VAD) information is from the OPTN Trans-
plant Recipient Registration Form and includes left VAD, right VAD, total artificial
heart, and left + right VAD. Collection of calculated PRA (CPRA) began March 31,
2015. Prior to that, PRA class I and II values were used.
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Characteristic
2005 2015
N Percent N Percent
Insurance
Private 1047 56.9% 1149 48.7%
Medicare 481 26.1% 819 34.7%
Medicaid 217 11.8% 285 12.1%
Other government 68 3.7% 68 2.9%
Unknown 28 1.5% 38 1.6%
Wait time
< 31 days 558 30.3% 553 23.4%
31-60 days 261 14.2% 311 13.2%
61-90 days 168 9.1% 206 8.7%
3-< 6 months 310 16.8% 394 16.7%
6-< 12 months 266 14.4% 403 17.1%
1-< 2 years 141 7.7% 321 13.6%
2-< 3 years 59 3.2% 99 4.2%
≥ 3 years 78 4.2% 72 3.1%
Medical urgency
Status 1A 609 33.1% 1565 66.3%
Status 1B 702 38.1% 732 31.0%
Status 2 530 28.8% 62 2.6%
On VAD 476 25.9% 1141 48.4%
Tx type
Heart only 1752 95.2% 2180 92.4%
Heart-lung 30 1.6% 12 0.5%
Heart-kidney 53 2.9% 140 5.9%
Heart-liver 5 0.3% 27 1.1%
Other 1 0.1% 0 0.0%
Table HR 5 Characteristics of adult heart transplant recipients, 2005 and
2015 (continued from previous page and onto next page). Adult heart trans-
plant recipients, including retransplants. Ventricular assist device (VAD) information
is from the OPTN Transplant Recipient Registration Form and includes left VAD,
right VAD, total artificial heart, and left + right VAD. Collection of calculated PRA
(CPRA) began March 31, 2015. Prior to that, PRA class I and II values were used.
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Characteristic
2005 2015
N Percent N Percent
HLA mismatches
0 1 0.1% 1 0.0%
1 5 0.3% 7 0.3%
2 44 2.4% 73 3.1%
3 169 9.2% 259 11.0%
4 418 22.7% 564 23.9%
5 590 32.0% 796 33.7%
6 328 17.8% 485 20.6%
Unknown 286 15.5% 174 7.4%
CPRA
< 1% 1101 59.8% 1260 53.4%
1-< 20% 309 16.8% 313 13.3%
20-< 80% 217 11.8% 337 14.3%
80-< 98% 42 2.3% 62 2.6%
98-100% 48 2.6% 19 0.8%
Unknown 124 6.7% 368 15.6%
All recipients 1841 100.0% 2359 100.0%
Table HR 5 Characteristics of adult heart transplant recipients, 2005 and
2015 (continued from previous page). Adult heart transplant recipients, includ-
ing retransplants. Ventricular assist device (VAD) information is from the OPTN
Transplant Recipient Registration Form and includes left VAD, right VAD, total
artificial heart, and left + right VAD. Collection of calculated PRA (CPRA) began
March 31, 2015. Prior to that, PRA class I and II values were used.
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Donor Recipient CMV EBV HIV
D- R- 12.3% 0.7% 95.3%
D- R+ 17.8% 4.5% 0.2%
D- R unk 8.3% 0.6% 3.9%
D+ R- 18.9% 10.8% 0.0%
D+ R+ 29.4% 71.9% 0.0%
D+ R unk 13.0% 11.3% 0.0%
D unk R- 0.1% 0.0% 0.6%
D unk R+ 0.1% 0.2% 0.0%
D unk R unk 0.1% 0.0% 0.0%
Table HR 6 Adult heart donor-recipient serology matching, 2011-2015.
Donor serology is reported on the OPTN Donor Registration Form and recipient
serology on the OPTN Transplant Recipient Registration Form. There may be mul-
tiple fields per serology. Any evidence for a positive serology is treated as positive
for that serology. If all fields are unknown, incomplete, or pending, the person is
categorized as unknown for that serology; otherwise, serology is assumed negative.
CMV, cytomegalovirus; EBV, Epstein-Barr virus; HB, hepatitis B; HCV, hepatitis
C virus; HIV, human immunodeficiency virus.
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Characteristic
2005 2015
N Percent N Percent
Age
< 1 year 18 7.6% 45 14.0%
1-5 years 80 33.6% 100 31.2%
6-10 years 61 25.6% 68 21.2%
11-17 years 79 33.2% 108 33.6%
Sex
Female 93 39.1% 126 39.3%
Male 145 60.9% 195 60.7%
Race/ethnicity
White 146 61.3% 158 49.2%
Black 40 16.8% 64 19.9%
Hispanic 39 16.4% 80 24.9%
Asian 10 4.2% 9 2.8%
Other/unknown 3 1.3% 10 3.1%
Diagnosis
Congenital defect 97 40.8% 172 53.6%
Idiopathic dilated CM 67 28.2% 58 18.1%
Familial dilated CM 2 0.8% 9 2.8%
Idiopathic restrictive CM 7 2.9% 16 5.0%
Myocarditis 15 6.3% 5 1.6%
Other/unknown 50 21.0% 61 19.0%
Transplant history
First 222 93.3% 304 94.7%
Retransplant 16 6.7% 17 5.3%
Blood type
A 80 33.6% 97 30.2%
B 21 8.8% 38 11.8%
AB 5 2.1% 5 1.6%
O 132 55.5% 181 56.4%
Table HR 7 Characteristics of pediatric candidates on the heart trans-
plant waiting list on December 31, 2005 and December 31, 2015 (contin-
ued on next page). Candidates aged younger than 18 years waiting for transplant
on December 31, 2005, and December 31, 2015, regardless of first listing date; ac-
tive/inactive status is on this date, and multiple listings are not counted. CM,
cardiomyopathy; VAD, ventricular assist device.
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Characteristic
2005 2015
N Percent N Percent
Wait time
< 1 year 103 43.3% 200 62.3%
1-< 2 years 38 16.0% 55 17.1%
2-< 3 years 21 8.8% 28 8.7%
3-< 4 years 19 8.0% 15 4.7%
4-< 5 years 12 5.0% 6 1.9%
≥ 5 years 45 18.9% 17 5.3%
Medical urgency
Status 1A 25 10.5% 105 32.7%
Status 1B 17 7.1% 43 13.4%
Status 2 54 22.7% 57 17.8%
Inactive status 142 59.7% 116 36.1%
VAD at listing 5 2.1% 14 4.4%
Tx type
Heart only 215 90.3% 316 98.4%
Heart-kidney 1 0.4% 3 0.9%
Heart-lung 22 9.2% 1 0.3%
Other 0 0.0% 1 0.3%
All candidates 238 100.0% 321 100.0%
Table HR 7 Characteristics of pediatric candidates on the heart trans-
plant waiting list on December 31, 2005 and December 31, 2015 (contin-
ued from previous page). Candidates aged younger than 18 years waiting for
transplant on December 31, 2005, and December 31, 2015, regardless of first listing
date; active/inactive status is on this date, and multiple listings are not counted.
CM, cardiomyopathy; VAD, ventricular assist device.
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Waiting list state 2013 2014 2015
Patients at start of year 328 349 361
Patients added during year 591 593 644
Patients removed during year 568 579 635
Patients at end of year 351 363 370
Table HR 8 Heart transplant waitlist activity among pediatric candidates.
Candidates concurrently listed at more than one center are counted once, from the
time of earliest listing to the time of latest removal. Candidates who are listed,
undergo transplant, and are relisted are counted more than once. Candidates are
not considered to be on the list on the day they are removed; counts on January
1 may differ from counts on December 31 of the prior year. Candidates listed for
multi-organ transplants are included.
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Removal reason 2013 2014 2015
Deceased donor transplant 418 422 463
Patient died 53 77 80
Patient refused transplant 2 1 3
Improved, transplant not needed 47 43 48
Too sick for transplant 30 29 24
Other 18 7 17
Table HR 9 Removal reason among pediatric heart transplant candidates.
Removal reason as reported to the OPTN. Candidates with death dates that precede
removal dates are assumed to have died waiting.
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Characteristic
2002-05 2012-15
N Percent N Percent
Age
< 1 year 307 25.5% 470 28.4%
1-5 years 270 22.4% 385 23.3%
6-10 years 183 15.2% 250 15.1%
11-17 years 443 36.8% 548 33.2%
Sex
Female 568 47.2% 749 45.3%
Male 635 52.8% 904 54.7%
Race/ethnicity
White 678 56.4% 891 53.9%
Black 256 21.3% 323 19.5%
Hispanic 189 15.7% 321 19.4%
Asian 56 4.7% 77 4.7%
Other/unknown 24 2.0% 41 2.5%
Diagnosis
Congenital defect 540 44.9% 748 45.3%
Idiopathic dilated CM 381 31.7% 443 26.8%
Familial dilated CM 41 3.4% 76 4.6%
Idiopathic restrictive CM 72 6.0% 91 5.5%
Myocarditis 30 2.5% 64 3.9%
Other/unknown 139 11.6% 231 14.0%
Transplant history
First 1110 92.3% 1563 94.6%
Retransplant 93 7.7% 90 5.4%
Blood type
A 489 40.6% 599 36.2%
B 147 12.2% 226 13.7%
AB 46 3.8% 66 4.0%
O 521 43.3% 762 46.1%
ABO
Compatible/identical 1183 98.3% 1592 96.3%
Incompatible 20 1.7% 61 3.7%
Table HR 10 Characteristics of pediatric heart transplant recipients, 2002-
2005 and 2012-2015 (continued on next page). Heart transplant recipients,
including retransplants. Collection of calculated PRA (CPRA) began March 31,
2015. Prior to that, measured PRA values were used. CM, cardiomyopathy; VAD,
ventricular assist device.
67
     
Characteristic
2002-05 2012-15
N Percent N Percent
Insurance
Private 606 50.4% 725 43.9%
Medicaid 500 41.6% 766 46.3%
Other government 63 5.2% 121 7.3%
Unknown 34 2.8% 41 2.5%
Wait time
< 31 days 523 43.5% 485 29.3%
31-60 days 235 19.5% 310 18.8%
61-90 days 134 11.1% 228 13.8%
3-< 6 months 177 14.7% 321 19.4%
6-< 12 months 77 6.4% 197 11.9%
1-< 2 years 37 3.1% 75 4.5%
2-< 3 years 11 0.9% 21 1.3%
≥ 3 years 9 0.7% 16 1.0%
Medical urgency
Status 1A 866 72.0% 1465 88.6%
Status 1B 143 11.9% 134 8.1%
Status 2 194 16.1% 54 3.3%
On VAD 106 8.8% 407 24.6%
Tx type
Heart only 1171 97.3% 1627 98.4%
Heart-lung 22 1.8% 18 1.1%
Heart-kidney 9 0.7% 4 0.2%
Heart-liver 0 0.0% 4 0.2%
Other 1 0.1% 0 0.0%
CPRA
< 1% 633 52.6% 754 45.6%
1-< 20% 171 14.2% 278 16.8%
20-< 80% 104 8.6% 331 20.0%
80-< 98% 46 3.8% 89 5.4%
98-100% 37 3.1% 46 2.8%
Unknown 212 17.6% 155 9.4%
Table HR 10 Characteristics of pediatric heart transplant recipients, 2002-
2005 and 2012-2015 (continued from previous page and onto next page).
Heart transplant recipients, including retransplants. Collection of calculated PRA
(CPRA) began March 31, 2015. Prior to that, measured PRA values were used.
CM, cardiomyopathy; VAD, ventricular assist device.
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Characteristic
2002-05 2012-15
N Percent N Percent
All recipients 1203 100.0% 1653 100.0%
Table HR 10 Characteristics of pediatric heart transplant recipients, 2002-
2005 and 2012-2015 (continued from previous page). Heart transplant recip-
ients, including retransplants. Collection of calculated PRA (CPRA) began March
31, 2015. Prior to that, measured PRA values were used. CM, cardiomyopathy;
VAD, ventricular assist device.
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Support
2010 2015
N Percent N Percent
Any life support 236 65.6% 316 68.7%
Intravenous inotropes 178 49.4% 224 48.7%
Left ventricular assist device 62 17.2% 99 21.5%
Ventilator 58 16.1% 61 13.3%
Right ventricular assist device 24 6.7% 15 3.3%
Extra corporeal membrane oxygenation 16 4.4% 18 3.9%
Prostaglandins 6 1.7% 9 2.0%
Inhaled NO 3 0.8% 1 0.2%
Intra-aortic balloon pump 1 0.3% 0 0.0%
Total artificial heart 0 0.0% 2 0.4%
Table HR 11 Pediatric heart recipients on circulatory support before
transplant. Patients may have more than one type of circulatory support.
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Donor Recipient CMV EBV
D- R- 22.5% 13.3%
D- R+ 14.7% 14.0%
D- R unk 11.0% 1.2%
D+ R- 23.5% 29.7%
D+ R+ 16.9% 38.5%
D+ R unk 10.7% 3.0%
D unk R- 0.5% 0.4%
D unk R+ 0.1% 0.0%
D unk R unk 0.1% 0.0%
Table HR 12 Pediatric heart donor-recipient serology matching, 2011-
2015. Donor serology is reported on the OPTN Donor Registration Form and recip-
ient serology on the OPTN Translant Recipient Registration Form. There may be
multiple fields per serology. Any evidence for a positive serology is treated as posi-
tive for that serology. If all fields are unknown, incomplete, or pending, the person
is categorized as unknown for that serology; otherwise, serology is assumed negative.
CMV, cytomegalovirus; EBV, Epstein-Barr virus.
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